1 January 2024 in The Anatolian Journal of Cardiology
The incidence and mortality of cardiovascular diseases, of which coronary heart disease (CHD) is a significant cardiovascular burden, are on the rise. Pyroptosis as an incipient programmed cell death mediated by inflammasomes can sense cytoplasmic contamination or interference and is typically marked by intracellular swelling, plasma membrane blistering and intense inflammatory cytokine release. As research on pyroptosis continues to progress, there is mounting evidence that pyroptosis is a vital participant in the pathophysiological basis of CHD. Atherosclerosis is the major pathophysiological basis of CHD and involves pyroptosis of endothelial cells, macrophages, vascular smooth muscle cells, and other immune cells, often in association with the release of pro-inflammatory factors. When cardiomyocytes are damaged, it will eventually lead to heart failure. Previous studies have covered that pyroptosis plays a critical role in CHD. In this review, we describe the properties of pyroptosis, summarize its contribution and related targets to diseases involving angina pectoris, myocardial infarction, myocardial ischemia in perfusion injury and heart failure, and highlight potential drugs for different heart diseases.
30 January 2025 in Boletin Latinoamericano Y Del Caribe de Plantas Medicinales Y Aromaticas
SHShaoxing People'S Hospital
Shaoxing People'S Hospital
+6
This study investigates the efficacy and mechanisms of Kuanxiong Aerosol (KXA) on coronary microvascular dysfunction (CMD) in rats. Thirty-two Sprague-Dawley rats were divided into control, model, KXA, and nicorandil groups, receiving respective treatments for three weeks. The CMD model was established byinjecting lauric acid into the left ventricle. Compared to the model group, the KXA group showed significant reductions in serum CK-MB, LDH, cTnI, ET-1, TNF-α, IL-6, MDA, and ROS (p<0.01) and increased NO and SOD levels (p<0.01). KXA mitigated apoptosis and ameliorated CMD-associated pathological alterations. Pretreatment with KXA improves endothelial function and microvascular structure by counteracting inflammation, oxidative stress, and apoptosis, thereby improving CMD.